CBD and irritable bowel syndrome: the state of the research

The French national society of gastroenterology indicates that 5% of the adult population is thought to be affected by irritable bowel syndrome, with three women for every man, and a course of at least six months. The diagnosis is a diagnosis of exclusion. Among the approaches cited are antispasmodics, the low-FODMAP diet, effective in around half of patients, and hypnosis in refractory forms.

Recourse to healthcare is substantial. A study published in 2019 in BMC Gastroenterology, based on the national health insurance database, identified 29,509 patients among 43.7 million adults, 64% of whom had had a colonoscopy.

One point deserves noting from the outset: cannabidiol does not appear among the approaches listed by the French learned society.

A Dutch team published in 2022 in Cannabis and Cannabinoid Research a double-blind placebo-controlled crossover trial of a cannabidiol chewing gum. Let us clarify the format, often misreported: it was a chewing gum dosed at 50 mg, taken on demand, up to six per day, not gummies to swallow.

The trial included 32 participants, all women, of median age 31, over eight weeks in total with an intervening washout period. The primary endpoint was the within-individual change in pain thirty minutes after chewing.

The result is null. The mean within-individual difference between cannabidiol and placebo was 0.1, with a 95% confidence interval from minus 0.3 to 0.5, for a p-value of 0.61. On quality of life, the difference was minus 1.0, confidence interval minus 6.8 to 4.9, p-value 0.74.

The authors themselves point out limitations that forbid concluding the other way: average consumption remained below one chewing gum per day, the thirty-minute chewing proved impractical, and underdosing is possible. The honest wording is therefore this: cannabidiol demonstrated no effect at the only dose and in the only format tested, which is not the same thing as demonstrated inefficacy.

The first concerns palmitoylethanolamide, often cited in this context. A trial published in 2017 in Alimentary Pharmacology and Therapeutics evaluated a combination of palmitoylethanolamide and polydatin in 54 patients: its primary biological endpoint was not modified, with an improvement in pain appearing as a secondary endpoint. Above all, this molecule is an endogenous lipid mediator, neither a phytocannabinoid nor cannabidiol. Its results do not carry over.

The second concerns olorinab, cited as having reduced abdominal pain in one form of the syndrome. A review published in 2023 in Clinical Gastroenterology and Hepatology points out that it is a synthetic agonist of the CB2 receptor, not cannabidiol.

That same review contributes two useful elements. Cannabinoids tend overall to inhibit digestive motility. And cannabidiol did not significantly improve pain endpoints in functional dyspepsia, a second negative result on digestive pain.

Finally, there is no Cochrane review devoted to cannabinoids in irritable bowel syndrome.

The point is decisive for this particular subject, since the formats concerned would by nature be ingested. In a statement of 20 May 2026, the Ministry of Agriculture recalls that foodstuffs containing CBD are not authorised under the European novel food regulation, the safety of CBD not having been demonstrated, and that they must be withdrawn from the market. This withdrawal, applied under the control plan relayed by the chambers of agriculture from 15 May 2026, leaves only two categories standing: hemp seeds and their derivatives, and leaves intended for an aqueous infusion, without cannabinoid enrichment.

On the scientific side, EFSA published on 9 February 2026 a provisional safe dose of 0.0275 mg per kilogram of body weight per day, around 2 mg per day for a 70 kg adult, specifying that safety cannot be established for those under 25, pregnant or breastfeeding women and people on medication. That last reservation directly concerns a population frequently treated with antispasmodics or other medicines. We detail this milestone in our articles on EFSA's reference dose and on the applicable regulations.

Our articles on the gut-brain axis and on stomach aches address digestive comfort in a strictly non-medical setting.

Does CBD relieve irritable bowel syndrome?

Nothing allows that claim. The only published randomised trial, conducted in 32 women with a 50 mg chewing gum taken on demand, found no difference from placebo, either on pain, with a p-value of 0.61, or on quality of life, with a p-value of 0.74.

Can you buy CBD oils or gummies to swallow in France?

No. The Ministry of Agriculture recalled on 20 May 2026 that foodstuffs containing CBD are not authorised under the European novel food regulation and must be withdrawn from the market. Only hemp seeds and their derivatives, along with leaves for aqueous infusion, remain lawful as foods.

Can CBD worsen certain digestive symptoms?

That is a question for a doctor. The review published in 2023 in Clinical Gastroenterology and Hepatology notes that cannabinoids tend overall to inhibit digestive motility, and diarrhoea is among the adverse effects identified by EFSA. These elements matter particularly for the forms of the syndrome in which diarrhoea predominates.